209 related articles for article (PubMed ID: 11710634)
1. Etoposide induction of tumor immunity in Lewis lung cancer.
Slater LM; Stupecky M; Sweet P; Osann K; Eklof A; Arquilla ER
Cancer Chemother Pharmacol; 2001 Oct; 48(4):327-32. PubMed ID: 11710634
[TBL] [Abstract][Full Text] [Related]
2. Induction of highly immunogenic variants of Lewis lung carcinoma tumor by ultraviolet irradiation.
Peppoloni S; Herberman RB; Gorelik E
Cancer Res; 1985 Jun; 45(6):2560-6. PubMed ID: 2580624
[TBL] [Abstract][Full Text] [Related]
3. Adoptive transfer of anti-CD3-activated CD4+ T cells plus cyclophosphamide and liposome-encapsulated interleukin-2 cure murine MC-38 and 3LL tumors and establish tumor-specific immunity.
Saxton ML; Longo DL; Wetzel HE; Tribble H; Alvord WG; Kwak LW; Leonard AS; Ullmann CD; Curti BD; Ochoa AC
Blood; 1997 Apr; 89(7):2529-36. PubMed ID: 9116299
[TBL] [Abstract][Full Text] [Related]
4. Enhancement of leukemia rejection by mice successfully treated for L1210 leukemia due to low dose compared to high dose VP-16.
Slater LM; Stupecky M; Sweet P; Osann KE
Leuk Res; 2002 Feb; 26(2):203-6. PubMed ID: 11755470
[TBL] [Abstract][Full Text] [Related]
5. Involvement of doxorubicin-induced Fas expression in the antitumor effect of doxorubicin on Lewis lung carcinoma in vivo.
Yoshimoto Y; Kawada M; Ikeda D; Ishizuka M
Int Immunopharmacol; 2005 Feb; 5(2):281-8. PubMed ID: 15652759
[TBL] [Abstract][Full Text] [Related]
6. Tumor vaccination with macrophage colony-stimulating factor-producing Lewis lung carcinoma in mice.
Morita T; Ikeda K; Douzono M; Yamada M; Kimura F; Kawakami K; Sasaki K; Motoyoshi K; Takahara J; Irino S
Blood; 1996 Aug; 88(3):955-61. PubMed ID: 8704254
[TBL] [Abstract][Full Text] [Related]
7. Immune response against 3LL Lewis lung carcinoma potentiates the therapeutic efficacy of endostatin.
Li M; Huang X; Zhu Z; Wong M; Watkins S; Zhao Q; Herberman R; Gorelik E
J Immunother; 2001; 24(6):472-81. PubMed ID: 11759070
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of GM-CSF-producing tumor vaccine after docetaxel chemotherapy in mice bearing established Lewis lung carcinoma.
Chu Y; Wang LX; Yang G; Ross HJ; Urba WJ; Prell R; Jooss K; Xiong S; Hu HM
J Immunother; 2006; 29(4):367-80. PubMed ID: 16799332
[TBL] [Abstract][Full Text] [Related]
9. Cyclosporin A/VP-16 produced immunity to L1210 leukemia: the participation of cytotoxic CD8 T-lymphocytes.
Slater LM; Sweet P; Stupecky M; Reynolds JT
Clin Immunol Immunopathol; 1995 Jun; 75(3):239-45. PubMed ID: 7768041
[TBL] [Abstract][Full Text] [Related]
10. Autolymphocyte therapy. II. Dependence of in vivo anti-tumor specificity and long-term immunity against murine melanoma and carcinoma on ex vivo activated donor memory T-cells.
Gold JE; Osband ME
Clin Immunol Immunopathol; 1994 Jun; 71(3):325-32. PubMed ID: 7911078
[TBL] [Abstract][Full Text] [Related]
11. Superiority of cyclosporin A over PSC-833 in enhancement of VP-16 efficacy in murine tumors in vivo.
Slater LM; Sweet P; Stupecky M; Osann K
Cancer Chemother Pharmacol; 1997; 39(5):452-4. PubMed ID: 9054960
[TBL] [Abstract][Full Text] [Related]
12. Augmenting major histocompatibility complex class I expression by murine tumors in vivo enhances antitumor immunity induced by an active immunotherapy strategy.
Merritt RE; Yamada RE; Crystal RG; Korst RJ
J Thorac Cardiovasc Surg; 2004 Feb; 127(2):355-64. PubMed ID: 14762342
[TBL] [Abstract][Full Text] [Related]
13. Autolymphocyte therapy--I. In vivo tumour-specific adoptive cellular therapy of murine melanoma and carcinoma using ex vivo activated memory T-lymphocytes.
Gold JE; Osband ME
Eur J Cancer; 1994; 30A(12):1871-82. PubMed ID: 7880620
[TBL] [Abstract][Full Text] [Related]
14. Comparison between VP 16 and VM 26 in Lewis lung carcinoma of the mouse.
Colombo T; Broggini M; Vaghi M; Amato G; Erba E; D'Incalci M
Eur J Cancer Clin Oncol; 1986 Feb; 22(2):173-9. PubMed ID: 3699080
[TBL] [Abstract][Full Text] [Related]
15. Fractalkine transgene induces T-cell-dependent antitumor immunity through chemoattraction and activation of dendritic cells.
Guo J; Zhang M; Wang B; Yuan Z; Guo Z; Chen T; Yu Y; Qin Z; Cao X
Int J Cancer; 2003 Jan; 103(2):212-20. PubMed ID: 12455035
[TBL] [Abstract][Full Text] [Related]
16. Adoptively transferred ex vivo activated memory T cells with cyclophosphamide: effective tumor-specific chemoimmunotherapy of advanced metastatic murine melanoma and carcinoma.
Gold JE; Zachary DT; Osband ME
Clin Immunol Immunopathol; 1994 Oct; 73(1):115-22. PubMed ID: 7923908
[TBL] [Abstract][Full Text] [Related]
17. Autolymphocyte therapy. III. Effective adjuvant adoptive cellular therapy with in vivo anti-tumor specificity against murine melanoma and carcinoma using ex-vivo-activated memory T-lymphocytes.
Gold JE; Masters TR; Osband ME
J Surg Res; 1995 Aug; 59(2):279-86. PubMed ID: 7543632
[TBL] [Abstract][Full Text] [Related]
18. Development of cyclosporin A mediated immunity in L1210 leukaemia.
Slater LM; Wetzel M; Cho J; Sweet P
Br J Cancer; 1991 Dec; 64(6):1098-102. PubMed ID: 1764373
[TBL] [Abstract][Full Text] [Related]
19. ICRF-187 rescue in etoposide treatment in vivo. A model targeting high-dose topoisomerase II poisons to CNS tumors.
Holm B; Jensen PB; Sehested M
Cancer Chemother Pharmacol; 1996; 38(3):203-9. PubMed ID: 8646793
[TBL] [Abstract][Full Text] [Related]
20. Big tumor regression induced by GM-CSF gene-modified 3LL tumor cells via facilitating DC maturation and deviation toward CD11c+CD8alpha+ subset.
Lin Y; Xiong S; Zhang L; Zhang Y; Cai Y; Xu L; Chu Y
DNA Cell Biol; 2007 Dec; 26(12):863-72. PubMed ID: 17760559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
